However, the expression of SREBF1 was reduced in other tumors, such as adrenocortical carcinoma (ACC), colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), and uterine carcinosarcoma (UCS). Here, SREBF1 is linked to cutaneous melanoma.